Patients with unresectable locally advanced or metastatic squamous cell penile carcinoma
(SPC) who are in response or with stable disease after first line platinum containing
polychemotherapy who meet the inclusion/exclusion criteria will be offered to take part in
The patients may be pre-screened at the time of the 1st line chemotherapy.
In order for patients to be enrolled, the investigator must have carried out a radiological
assessment of the disease during first line systemic treatment (a maximum of between 3 and 6
cycles): the cancer must be controlled. Patients with disease progression cannot be included
in the PULSE study as this is a maintenance study.
After inclusion, Avelumab will be administered at a dose of 10 mg/kg, at a frequency of once
every 2 weeks with appropriate supportive care.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.